Dr. Gastman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 216-444-6900Fax+1 216-444-9419
Summary
- Dr Gastman is a double boarded Plastic Surgeon and Otolaryngologist with specific interests in the comprehensive care of soft tissue malignancies, such as melanoma, non-melanoma skin cancers, sarcomas and head and neck cancer. Currently, Dr. Gastman has helped to institute a successful melanoma and soft tissue cancer clinic housed at the Taussig Cancer Center, where patients can be seen by not only him for extirpative and reconstructive consults, but also by medical and radiation oncologists all in the same setting.
As a plastic surgeon he also specializes in complex reconstruction of the craniomaxillofacial skeleton, facial plastic surgery and is on the facial transplantation team. As an otolaryngologist, he uses his training to provide advanced treatment of nasal airway diseases as well as nasal reconstruction, e.g. rhinoplasty. Finally, Dr. Gastman also performs general reconstruction and cosmetic surgery of the trunk, abdomen and extremities and is an expert in non-surgical treatment of aging.
Education & Training
- UPMC Medical EducationResidency, Plastic Surgery - Integrated, 2003 - 2005
- Washington University/B-JH/SLCH ConsortiumFellowship, Reconstructive Microsurgery, 2002 - 2003
- UPMC Medical Education (Pittsburgh)Residency, Otolaryngology - Head and Neck Surgery, 1997 - 2002
- UPMC Medical EducationInternship, Transitional Year, 1996 - 1997
- University of Michigan Medical SchoolClass of 1996
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- OH State Medical License 2010 - 2027
- MD State Medical License 2005 - 2018
- PA State Medical License 1997 - 2006
- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
- American Board of Plastic Surgery Plastic Surgery
Awards, Honors, & Recognition
- Innovator Award Cleveland Clinic, 2011
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
- Top Surgical Activity Maryland General Hospital, 2007
- Join now to see all
Clinical Trials
- Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial Start of enrollment: 2018 Nov 15
- High-Risk Skin Cancers With Atezolizumab Plus NT-I7 Start of enrollment: 2019 Dec 26
- Surgical Site Infection and Antibiotic Use Study Start of enrollment: 2021 May 07
- Join now to see all
Publications & Presentations
PubMed
- Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.Charles H Yoon, Merrick I Ross, Brian R Gastman, Jason J Luke, Paolo A Ascierto
Annals of Surgical Oncology. 2025-02-01 - Germline Pathogenic Variant-Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy.Alan Shen, Michelle Arbesman, Roshan Lodha, Patricia Rayman, Brian Gastman
The Journal of Investigative Dermatology. 2025-01-13 - 1 citationsOpen-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-...Caroline Robert, Brian Gastman, Helen Gogas, Piotr Rutkowski, Georgina V Long
European Journal of Cancer. 2024-08-01
Press Mentions
- Research Finds VISTA Directly Blocks T-cells from Functioning in ImmunotherapyMay 17th, 2024
- She Thought Cancer Had Won — Until This Experimental TherapyNovember 11th, 2022
- Here’s What Skin Cancer Looks like, Dermatologists Say — Eat This Not ThatApril 9th, 2022
- Join now to see all
Grant Support
- Tumor Induced Senescent And Suppressor T Cells - A Novel Mechanism Of Immune EvasNational Cancer Institute2010–2011
- Tumor Induced Senescent And Suppressor T Cells - A Novel Mechanism Of Immune EvasNational Cancer Institute2008–2009
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: